pubmed.ncbi.nlm.nih.gov

Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts - PubMed

Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts

Tetsuya Hamaguchi et al. Cancer Sci. 2004 Jul.

Abstract

MCC-465 is an immunoliposome-encapsulated doxorubicin. The liposome is tagged with polyethylene glycol and the F(ab')2 of a monoclonal antibody named GAH, a human antibody obtained by the hybridoma technique. The epitope recognized by GAH is not well characterized, but human gastric, colorectal, and mammary cancer cells were GAH-positive, while the normal counterparts were GAH-negative. Pegylated liposome doxorubicin (PLD) and MCC-465 did not show significant antitumor activity against GAH-negative Caco-2 xenografts. On the other hand, MCC-465 exhibited significantly superior antitumor effects against GAH-positive WiDr-Tc and SW837 xenografts, compared with PLD. Immunohistochemistry with GAH revealed that 94% (100 of 106) of surgical specimens of colorectal cancer were GAH-positive. These results warrant a phase I clinical trial of MCC-465 for patients with metastatic colorectal cancer.

PubMed Disclaimer

Cited by

Liposomes as nanomedical devices.
Bozzuto G, Molinari A. Bozzuto G, et al. Int J Nanomedicine. 2015 Feb 2;10:975-99. doi: 10.2147/IJN.S68861. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25678787 Free PMC article. Review.
Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy.
Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z, Fan Z, Li J. Li J, et al. Pharmaceutics. 2023 Aug 29;15(9):2233. doi: 10.3390/pharmaceutics15092233. Pharmaceutics. 2023. PMID: 37765202 Free PMC article. Review.
The big picture on nanomedicine: the state of investigational and approved nanomedicine products.
Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. Etheridge ML, et al. Nanomedicine. 2013 Jan;9(1):1-14. doi: 10.1016/j.nano.2012.05.013. Epub 2012 Jun 6. Nanomedicine. 2013. PMID: 22684017 Free PMC article. Review.
The role of ferroptosis in cardio-oncology.
Hou K, Liu L, Fang ZH, Zong WX, Sun D, Guo Z, Cao L. Hou K, et al. Arch Toxicol. 2024 Mar;98(3):709-734. doi: 10.1007/s00204-023-03665-3. Epub 2024 Jan 5. Arch Toxicol. 2024. PMID: 38182913 Review.
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.
Immordino ML, Dosio F, Cattel L. Immordino ML, et al. Int J Nanomedicine. 2006;1(3):297-315. Int J Nanomedicine. 2006. PMID: 17717971 Free PMC article. Review.

References

1. Cancer Statistics in Japan '03. http://www.ncc.go.jp/en/statistics/2003/index.html.
1. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238–52. - PubMed
1. Allen TM, Hansen C, Martin F, Redemann C, Yau‐young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half‐lives in vivo . Biochim- Biophys Acta 1991; 1066: 29–36. - PubMed
1. Maruyama K, Yuda T, Okamoto A, Kojima S, Suginaka A, Iwatsuru M. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim. Biophys Acta 1992; 1128: 44–9. - PubMed
1. Gabizon A, Catane R, Uziely B, Kafman B, Safra T, Cohen R, Martin F, Huang A, Balenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene‐gly‐col coated liposomes. Cancer Res 1994; 54: 987–92. - PubMed

Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts - PubMed